Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate

Rau, Rolf; Simianer, S.; Riel, P.L.C.M. van; Putte, L.B.A. van de; Krüger, Klaus; Schattenkirchner, M; Allaart, Cornelia F; Breedveld, F. C.; Kempeni, Joachim; Beck, Kelly von; Küpper, H.

doi:10.1080/03009740410005467

Cited by 39 publications

(17 citation statements)

References 10 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of these biologicals has been evaluated in clinical trials using classical clinical outcome measures such as ACR20, HAQ, X-ray scores and DAS28 [1, 2]. Incorporating outcome measures such as DAS scores, imaging, as well as an evaluation of the patient’s quality of life has changed treatment targets in clinical practice and improved patient outcome.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study

Mits

Lenaerts²,

Cruyssen

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

ObjectivesBiological treatment of rheumatoid arthritis (RA) is one of the cornerstones of current treatment strategies for the disease. Surprisingly little information exists on whether the route of administration affects patients’ treatment satisfaction. It is equally unclear whether rheumatologists are able to accurately perceive their patients’ appreciation. Thus, the Belgian Be-raise survey aimed to examine whether RA patient’s experience of their current biological treatment coincided with the treating physician’s perception.MethodsA nationwide cross-sectional survey was conducted by 67 Belgian rheumatologists providing data obtained from 550 RA patients. Patients under stable dose of biologics for at least 6 months, were enrolled consecutively and all completed questionnaires. Separate questionnaires were completed by the treating rheumatologist which evaluated their patient’s perception of the route of treatment administration. This study therefore evaluates whether a treating physician perceives the satisfaction with the route of administration to the same degree as the patient.ResultsCompleted questionnaires were obtained from 293 and 257 patients who obtained treatment via the intravenous (IV) or subcutaneous (SC) route of administration, respectively. 58.4% of patients were in DAS28-CRP(3) remission. Patient satisfaction with disease control was higher (44% scored ≥ 9) than that of the treating physician (35%), regardless of the route of administration (p< 0.01). No differences were seen for the patients treated with an IV as opposed to a SC route of administration. The physician´s perception of patient’s satisfaction with disease control was markedly lower for IV treated patients as opposed to SC treated patients (p< 0.001).ConclusionsPatients’ satisfaction with biological treatment is high, but there is a considerable mismatch between patients´ and rheumatologists´ appreciation on the route of administration of biological therapy in RA. Physicians consistently consider IV biological therapy to be less satisfactory. Patient´s appreciation is largely dependent on disease control, irrespective of the route of administration. Therefore, and encouraging shared decision making, we suggest that physicians and patients discuss the route of administration of biologicals in an open way.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In this context, several studies have investigated the efficacy and safety of different biological therapies available in either IV or SC formula (eg. abatacept, golimumab, adalimumab, tocilizumab) and found no difference between these modes of administration [2, 4–6]. …”

Section: Introductionmentioning

confidence: 99%

A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study

Mits

Lenaerts²,

Cruyssen

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Controlled trials have shown that adalimumab is safe and effective for treating rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis. [18][19][20][21][22][23][24][25] Adalimumab is approved by multiple regulatory authorities for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Adalimumab was approved in the United States in February 2007 for the treatment of moderate to severe Crohn's disease.…”

mentioning

confidence: 99%

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

Sandborn¹,

Hanauer

Rutgeerts

et al. 2007

Gut

887

573

View full text Add to dashboard Cite

show abstract

“…Several clinical trials of RA patients demonstrated clinical and radiographic efficacy and safety of adalimumab in combination with standard antirheumatic therapy, including MTX 9,10,12,13,14,15,16 , and as monotherapy 17 . In a randomized controlled study of patients with established RA who had an inadequate response to initial treatment with MTX (DE019), adalimumab plus MTX was significantly more effective than MTX alone in reducing clinical signs and symptoms, improving physical function, and inhibiting radio graphic disease progression 9 .…”

mentioning

confidence: 99%

Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis

Keystone

Kavanaugh²,

Weinblatt³

et al. 2011

J Rheumatol

View full text Add to dashboard Cite

Objective.This Year 5 analysis of an open-label extension (OLE) study assessed radiographic progression, clinical efficacy, and safety of adalimumab with concomitant methotrexate (MTX) for patients with active rheumatoid arthritis.Methods.In a double-blind study (DE019, NCT00195702), inadequate responders to MTX were randomized to MTX plus either adalimumab 40 mg eow, adalimumab 20 mg weekly, or placebo for 52 weeks. Eligible patients entered an ongoing OLE and received adalimumab 40 mg eow plus MTX. Longterm efficacy and safety were evaluated.Results.Of 457 patients who had enrolled in the OLE, 304 remained in the study at Year 5, including 112, 107, and 85 from the original adalimumab 40 mg, adalimumab 20 mg, and placebo groups, respectively. Year 5 radiographs demonstrated mean changes in modified total Sharp score for the original adalimumab 40 mg eow and 20 mg weekly groups of 0.8 and 2.6, respectively, versus 3.9 for placebo; 58% from the adalimumab 40 mg eow group had no radiographic progression versus 40% of those who initially received placebo. Of patients who received adalimumab 40 mg eow for 5 years, 26.1% achieved clinical remission (Disease Activity Score 28-joint count < 2.6), had no radio graphic progression (change in modified total Sharp score ≤ 0.5), and had normal function (Health Assessment Questionnaire ≤ 0.5), versus 11.9% of those who initially received placebo. Serious infection rate for 553 patients who received at least one dose of adalimumab was 4.4/100 patient-years.Conclusion.A 52-week delay in adding adalimumab to MTX led to worse radiographic, functional, and clinical outcomes at Year 5 for most patients who initially received placebo instead of adalimumab.

show abstract

Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate

Abstract: Either i.v. or s.c. adalimumab added to MTX significantly improved the signs and symptoms of RA compared with MTX alone. Subcutaneously administered adalimumab appeared to provide a response that was as great, as rapid, and as enduring as that with i.v. adalimumab.

Cited by 39 publications

References 10 publications

A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study

A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis

Contact Info

Product

Resources

About